Evidence map›Paper›PMID 28344874›Full record

ArticleOncoimmunology

High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette-Guerin therapy: A long-term survival analysis.

Kai Qu, Jian Gu, Yuanqing Ye, Stephen B Williams, Colin P Dinney, Xifeng Wu, Ashish Kamat

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Review of BCG immunotherapy for bladder cancer.Clinical microbiology reviews · 2025
    Review
  3. Observational
  4. Bladder cancer biomarkers.Exploration of targeted anti-tumor therapy · 2025
    Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Kai QuDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, China.
Jian GuDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center , Houston, TX, USA.
Yuanqing YeDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center , Houston, TX, USA.
Stephen B WilliamsDepartment of Urology, The University of Texas MD Anderson Cancer Center , Houston, TX, USA.
Colin P DinneyDepartment of Urology, The University of Texas MD Anderson Cancer Center , Houston, TX, USA.
Xifeng WuDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center , Houston, TX, USA.
Ashish KamatDepartment of Urology, The University of Texas MD Anderson Cancer Center , Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · USFirst Affiliated Hospital of Xi'an Jiaotong University · CN

Funding

Targeting Ral GTPases in Bladder CancerP50CA091846 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DINNEY, COLIN P.N., MCCONKEY, DAVID J. · 2001 to 2018
$37.4M
Genome-Wide Association Analysis of Bladder CancerU01CA127615 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WU, XIFENG · 2008 to 2012
$5.1M
NCI NIH HHS P50 CA091846NCI NIH HHS U01 CA127615
6 · The paper itself

Abstract

Bacillus Calmette-Guerin (BCG) therapy for non-muscle invasive bladder cancer (NMIBC) can significantly reduce the risk of recurrence and progression. However, BCG therapy may fail in up to a half of treated patients and may also cause toxicities. Biomarkers to predict the effectiveness of BCG therapy are desired to pre-select patients for BCG therapy to maximize efficacy while avoid unnecessary toxicity. Twelve cytokines were measured in 100 blood and 112 urine samples using cytokine antibody array and correlated with recurrence-free survival in overall and BCG-treated NMIBC patients. Of the 12 cytokines, interleukin (IL) -2, IL-8, IL-10, tumor necrosis factor (TNF)-α, granulocyte-macrophage colony-stimulating factor (GM-CSF) and interferon (IFN)-γ were measurable in more than 30% of peripheral blood leukocyte (PBL) samples. Only IL-8 in PBL was found to be significantly associated with tumor recurrence, especially in those who receiving BCG therapy (hazard ratio [HR] = 4.24; 95% confidence interval [95%CI] = 1.65-10.88;

Indexed as

Antibody arrayBCG therapybladder cancerIL-8tumor recurrence

Identifiers

PMID28344874
PMCPMC5353920
OpenAlexW2564175379

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.